This content is machine translated ICML 2017 in Lugano Long-term data are positive At the ICML Congress, the audience gained insight into long-term data from two phase III trials in mantle cell lymphoma and chronic lymphocytic leukemia. The new results confirm the statements…
View Post 7 min This content is machine translated 10th Iron Academy, Zurich Iron deficiency in pregnancy and postpartum In Switzerland, about 32% of all pregnant women have an iron deficiency, which together with the resulting anemia can cause complications for mother and child. Oral and intravenous iron preparations…
View Post 3 min This content is machine translated Acute lymphoblastic leukemia Bispecific antibody in heavily pretreated patients. Blinatumomab forms a bridge between T cells and cancer cells. The bispecific antibody is proving its worth in a new phase III trial. It has been approved in Switzerland for…
View Post 7 min This content is machine translated Treatment of hemophilia New techniques to extend the half-life Prophylactic treatment with factor concentrates is now standard in the treatment of patients with severe hemophilia A. Conventional factor VIII and factor IX concentrates have a relatively short half-life and…
View Post 5 min This content is machine translated ASH 2016 in San Diego Multiple Myeloma Review As every year, the ASH Congress took place in the busy pre-Christmas season. This time, experts from hematology and oncology met in San Diego. Multiple myeloma was again an important…
View Post 10 min This content is machine translated Preoperative anemia in the era of patient blood management (PBM). A pragmatic approach to diagnostics and therapy Preoperative anemia is an independent predictor of increased risk of infection, thromboembolism, and mortality. For their part, allogeneic blood transfusions further contribute to worsening outcomes through nonspecific and specific risks.…
View Post 6 min This content is machine translated Chronic myeloid leukemia State of the Art – where are we at CML in 2017? CML patients have a normal life expectancy when treated with Abl-specific kinase inhibitors (TKIs) in chronic phase. Imatinib, dasatinib and nilotinib are approved in the first-line treatment of CML. In…
View Post 6 min This content is machine translated Often recognized and treated too late Acute porphyrias – update on diagnosis and therapy Porphyrias are a group of very rare, genetically determined metabolic diseases with a disorder of heme biosynthesis. The typical symptom triad in a relapse consists of abdominal pain, cerebral symptoms,…
View Post 5 min This content is machine translated EHA Congress in Copenhagen New therapeutic options and improved survival in acute leukemias This year, the congress of the European Hematology Association (EHA) was held in Copenhagen from June 9-12. We report encouraging study results on the therapy of AML in elderly patients…
View Post 3 min This content is machine translated Chronic myeloid leukemia When is it possible to stop therapy? Most patients with CML are dependent on therapy with a tyrosine kinase inhibitor for the rest of their lives. However, there is increasing research into when and in which patients…
View Post 3 min This content is machine translated Venous thromboembolism with suspected cancer Are increased screening efforts useful? Idiopathic venous thromboembolism may be early warning signs of tumor. According to older studies, up to 10% of those affected are diagnosed with cancer in the year following thrombosis [1].…
